FIELD: pharmaceutics.
SUBSTANCE: invention relates to the use of chiglitazar or its pharmaceutically acceptable salts for the manufacture of a drug for the treatment of fibrotic diseases, including fibrotic diseases caused by damage to tissue cells as a result of chronic inflammation, such as systemic scleroderma, chronic nephritis and kidney fibrosis, myelofibrosis, idiopathic pulmonary fibrosis and non-alcoholic fatty liver infiltration, as well as for the manufacture of a fibroblast inhibitor, for the manufacture of an inhibitor of mediated TGFß activation of extracellular matrix of fibroblasts, for the manufacture of an inflammatory factor inhibitor in the manufacture of a monocyte chemotaxis inhibitor. Compared with the known starting compounds, chiglitazar demonstrates more significant and different activity characteristics and has a better potential for use in the treatment of fibrotic disease.
EFFECT: expansion of the range of drugs against fibrotic diseases.
8 cl, 10 dwg, 4 tbl, 6 ex
Title | Year | Author | Number |
---|---|---|---|
ANTI-CCR2 ANTIBODIES | 2009 |
|
RU2547595C2 |
COMBINED THERAPY WITH APPLICATION OF CENICRIVIROC FOR FIBROSIS TREATMENT | 2015 |
|
RU2723559C2 |
COMPOSITION FOR TREATING FIBROTIC DISEASES CONTAINING BENZHYDRYLTHIOACETAMIDE AS ACTIVE INGREDIENT | 2019 |
|
RU2769364C1 |
MATERIALS AND METHODS OF TREATING CHRONIC FIBROUS DISEASES | 2006 |
|
RU2446825C2 |
ANTAGONISTS OF ALPHAVBETA3 AND ALPHAVBETA6 INTEGRINS AND ANTIFIBROTIC AGENTS | 2004 |
|
RU2388472C2 |
AGONISTS OF NICOTINE RECEPTORS IN TREATMENT OF INFLAMMATORY DISEASES | 2002 |
|
RU2299731C2 |
PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NON-ALCOHOLIC STEATHOEPATITIS | 2021 |
|
RU2803733C1 |
INTEGRIN ανβ8 NEUTRALISING ANTIBODIES | 2011 |
|
RU2565539C2 |
METHOD OF TREATING AND PREVENTING FIBROSIS BY IL-21/IL-21R ANTAGONISTS | 2006 |
|
RU2419450C2 |
APPLYING OLTIPRAZ FOR PROPHYLAXIS AND TREATMENT OF LIVER FIBROSIS AND CIRRHOSIS AND OLTIPRAZ-CONTAINING PHARMACEUTICAL COMPOSITION | 2001 |
|
RU2258509C2 |
Authors
Dates
2022-03-31—Published
2019-09-20—Filed